کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2137696 | 1087856 | 2010 | 8 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Preclinical antileukemia activity of JNJ-26481585, a potent second-generation histone deacetylase inhibitor
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
موضوعات مرتبط
علوم زیستی و بیوفناوری
بیوشیمی، ژنتیک و زیست شناسی مولکولی
تحقیقات سرطان
پیش نمایش صفحه اول مقاله
![عکس صفحه اول مقاله: Preclinical antileukemia activity of JNJ-26481585, a potent second-generation histone deacetylase inhibitor Preclinical antileukemia activity of JNJ-26481585, a potent second-generation histone deacetylase inhibitor](/preview/png/2137696.png)
چکیده انگلیسی
Histone deacetylase (HDAC) inhibitors have been shown to induce cell cycle arrest, terminal differentiation, and apoptosis in a broad spectrum of human tumors and animal xenograft models. JNJ-26481585 is a hydroxamic acid derivative, second-generation pan-HDAC inhibitor that has demonstrated high potency in preclinical studies. In the current study, we demonstrated that JNJ-26481585 has antileukemia and molecular activity in leukemia cell lines and primary human leukemia cells. We also observed a synergistic effect between treatment with decitabine and JNJ-26481585. In conclusion, JNJ-26481585 is a potent second-generation pan-HDAC inhibitor with activity in human leukemia, and it is currently in clinical development.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Leukemia Research - Volume 34, Issue 2, February 2010, Pages 221–228
Journal: Leukemia Research - Volume 34, Issue 2, February 2010, Pages 221–228
نویسندگان
Wei-Gang Tong, Yue Wei, William Stevenson, Shao-Qing Kuang, Zhihong Fang, Ming Zhang, Janine Arts, Guillermo Garcia-Manero,